Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ACOG

Alpha Cognition Inc

Apr 28 • 04:00PM ET

6.20

-0.23 -3.58 %

Healthcare • Biotechnology • USA • Micro • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	16.36%	Shs Outstand	21.74M	Perf Week	-9.88%
Market Cap	135.00M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	11.55%	Shs Float	12.99M	Perf Month	22.05%
Enterprise Value	68.89M	PEG	-	EPS next Q	-0.39	Inst Own	74.50%	Short Float	1.58%	Perf Quarter	5.17%
Income	-20.67M	P/S	13.21	EPS this Y	-16.81%	Inst Trans	5.39%	Short Ratio	2.98	Perf Half Y	-9.75%
Sales	10.22M	P/B	2.16	EPS next Y	67.07%	ROA	-31.69%	Short Interest	0.21M	Perf YTD	-4.62%
Book/sh	2.88	P/C	2.04	EPS next 5Y	-	ROE	-39.75%	52W High	11.54 -46.27%	Perf Year	23.75%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	35.73% 45.28%	ROIC	-33.06%	52W Low	4.50 37.78%	Perf 3Y	48.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	77.40%	Volatility	6.42% 9.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.74	EPS Y/Y TTM	42.19%	Oper. Margin	-221.72%	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.07	Sales Y/Y TTM	-	Profit Margin	-202.24%	RSI (14)	47.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.63	EPS Q/Q	37.58%	SMA20	-4.27%	Beta	2.47	Target Price	16.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.66%	Rel Volume	1.22	Prev Close	6.43
Employees	71	LT Debt/Eq	0.00	Earnings	Mar 26 AMC	SMA200	-9.69%	Avg Volume	69.02K	Price	6.20
IPO	Jun 28, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-16.04% -12.50%	Trades		Volume	84,124	Change	-3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-26	Initiated	Craig Hallum	Buy	$14
Mar-18-25	Initiated	H.C. Wainwright	Buy	$20

Today 04:30PM	Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026 (Business Wire)
Apr-27-26 08:00AM	Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences (Business Wire) -6.20%
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Apr-15-26 08:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-26 04:21PM	Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock? (Quartz)
04:30PM	Loading…
Apr-01-26 04:30PM	Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury (Business Wire) +8.56%
09:51AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425 (Newsfile)
Mar-27-26 08:30AM	Alpha Cognition Inc. Common Stock Q4 2025 Earnings Call Summary (Moby)
Mar-26-26 04:01PM	Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update (Business Wire)
Mar-13-26 01:46PM	Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 (Business Wire)
Mar-10-26 08:30AM	Alpha Cognition to Present New Clinical on ZUNVEYL (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences (Business Wire)
Feb-25-26 08:30AM	Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study (Business Wire) +5.41%
Feb-18-26 08:30AM	Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens (Business Wire) +11.32%
Jan-07-26 04:30PM	Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution (Business Wire) +5.18%
Dec-05-25 09:40AM	Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? (Zacks)
05:51PM	Loading…
Dec-01-25 05:51PM	Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners (Business Wire) -6.15%
Nov-19-25 09:41AM	Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-14-25 09:46AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025 (Newsfile)
Nov-13-25 06:40PM	Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Nov-12-25 07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
07:30AM	Alpha Cognition Inc (ACOG) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-30-25 08:30AM	Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025 (Business Wire) -5.94%
Oct-15-25 09:00AM	Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference (NewMediaWire)
Oct-14-25 04:30PM	Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings (Business Wire)
Oct-06-25 08:30AM	Alpha Cognition to Present Clinical Data at ASCP Annual Meeting (Business Wire)
Sep-30-25 11:14PM	Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares (Business Wire) +13.21%
04:58PM	Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares (Business Wire)
Aug-28-25 01:00PM	Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences (Business Wire)
Aug-15-25 05:10PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025 (Newsfile) +5.56%
06:55PM	Loading…
Aug-14-25 06:55PM	Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -19.92%
08:30AM	Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Aug-04-25 08:30AM	Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Jul-29-25 08:30AM	Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL (Benzgalantamine) for Alzheimers Disease (Business Wire)
Jul-08-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Study Data at Alzheimers Association International Conference (Business Wire) -5.07%
Jul-04-25 12:00PM	What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock (Zacks)
Jul-01-25 05:05PM	Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire) +16.20%
09:40AM	Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-16-25 09:55AM	Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross? (Zacks)
Jun-06-25 04:31PM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
May-19-25 10:25AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 (Newsfile) +15.61%
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +27.02%
08:30AM	Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
May-01-25 08:30AM	Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview (Business Wire) +8.33%
Apr-30-25 07:30AM	Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference (Business Wire)
Apr-10-25 08:30AM	Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens (Business Wire)
Apr-01-25 04:27PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 (Newsfile)
Mar-31-25 09:50PM	Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript (Seeking Alpha) -8.50%
08:30AM	Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-19-25 04:30PM	Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-18-25 08:30AM	Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease (Business Wire)
Mar-05-25 08:35AM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
Feb-12-25 08:30AM	Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimers disease (Business Wire)
Jan-30-25 11:05AM	Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) (Newsfile) -5.06%
Jan-22-25 07:00AM	OTC Markets Group Announces Quarterly Index Performance and Rebalancing (GlobeNewswire)
Jan-14-25 08:30AM	Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL (Business Wire)
Jan-08-25 08:30AM	Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimers Disease, in China (Business Wire)
Jan-06-25 08:30AM	Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call (Business Wire)
Dec-16-24 02:56PM	Alpha Cognition Announces Partial Exercise of Over-allotment Option (Business Wire) -11.62%
Dec-12-24 06:41PM	Alpha Cognition Announces Voluntary Delisting from CSE (Business Wire) -5.57%
Dec-11-24 08:30AM	Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire)
Nov-15-24 05:00PM	Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update (Business Wire) -5.38% +6.15%
Nov-12-24 09:22AM	Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing (Business Wire) -32.14%

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal ("ALPHA-1062IN") formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Mar 27 '26	Buy	5.08	10,000	50,792	2,470,000	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 30 '26	Buy	4.99	1,850	9,227	2,471,850	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 25 '26	Buy	5.43	8,581	46,579	2,452,681	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 26 '26	Buy	5.28	7,319	38,675	2,460,000	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 24 '26	Buy	5.59	4,182	23,377	2,444,100	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 18 '26	Buy	5.75	2,481	14,263	2,437,824	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 19 '26	Buy	5.71	2,094	11,950	2,439,918	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 16 '26	Buy	5.78	1,331	7,696	2,435,343	Mar 18 06:55 PM
Opaleye Management Inc.	10% Owner	Mar 13 '26	Buy	5.75	7,358	42,286	2,434,012	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 12 '26	Buy	5.85	5,708	33,416	2,426,654	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 09 '26	Buy	5.85	2,179	12,742	2,420,946	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 06 '26	Buy	5.80	1,900	11,018	2,418,767	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 05 '26	Buy	5.80	47,023	272,621	2,416,867	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 04 '26	Buy	5.81	19,795	115,001	2,374,844	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Buy	5.75	51,411	295,624	2,355,049	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 02 '26	Buy	5.80	20,000	116,000	2,308,638	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Buy	5.99	3,638	21,797	2,288,638	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 26 '26	Buy	5.99	590	3,531	2,285,000	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 23 '26	Buy	5.89	100,000	589,230	2,230,819	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 24 '26	Buy	5.80	58,591	339,851	2,284,410	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 20 '26	Buy	5.84	12,819	74,877	2,135,000	Feb 24 05:52 PM
Wills Robert James	Director	Aug 18 '25	Buy	8.49	15,000	127,328	15,000	Aug 21 12:36 PM
MERTZ PHILLIP JOSEPH	Director	Aug 18 '25	Sale	9.00	27,778	250,002	22,462	Aug 20 04:26 PM
MERTZ LEONARD POWELL	Director	Aug 18 '25	Buy	9.00	27,778	250,002	121,503	Aug 20 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACOG

Alpha Cognition Inc

Upgrade your Finviz experience